Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

onartuzumab

- PMLiVE

Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy

Pancreatic cancer is the third leading cause of cancer-related deaths, with over 430,000 deaths each year

- PMLiVE

Sanofi and Innovent Biologics to develop oncology drugs for patients in China

Sanofi will make an initial equity investment of €300m in Innovent

- PMLiVE

Boehringer Ingelheim and QUANTRO Therapeutics partner to develop drug candidates

The collaboration aims to offer a long-term strategy to provide breakthrough cancer treatments

- PMLiVE

Roche’s Tecentriq demonstrates positive phase 3 results as a subcutaneous injection

Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion

- PMLiVE

Abstract Highlights from EHA 2022 : A Spotlight on CLL

Spotlight on CLLAhead of EHA 2022, Medscape Education Chief Medical Officer, Hansa Bhargava, MD, caught up with Prof John Gribben, UK, on the most important abstracts to look out for in...

Medscape Education Global

- PMLiVE

Roche’s Vabysmo recommended for EU approval by CHMP for sight loss

If approved, Vabysmo would be the first mechanism of action for nAMD and DME in the EU for over ten years

- PMLiVE

Roche’s diagnostic test for Alzheimer’s receives FDA Breakthrough Device Designation

Alzheimer's affects more than 55 million people globally and is the most common form of dementia

- PMLiVE

The White House reveals its ‘Cancer Cabinet’ line-up as its Moonshot initiative progresses

The panel includes its new chairperson, Elizabeth Jaffee, Mitchel Berger and Carol Brown

- PMLiVE

Researchers create ‘world’s largest’ database for predicting cancer treatment response

The database will be available to cancer researchers and clinicians around the world

- PMLiVE

Roche announces two-year data confirming Vabysmo improves neovascular age-related macular degeneration

The data showed, after two years, that 60% of patients treated with Vabysmo could be treated every four months, compared with 45% in year one

- PMLiVE

Bristol Myers Squibb’s Opdivo given NICE recommendation for urothelial cancer treatment

The treatment will be available on the NHS as an adjuvant treatment for those at high-risk of recurrence

- PMLiVE

Roche’s Lunsumio granted Priority Review by FDA for people with relapsed or refractory follicular lymphoma

If approved, this could be the first such antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links